New Milford, CT, United States of America

John David Ginn

This inventor holds 14 USPTO granted patents and 6 published patent applications, plus 2 CIPO patents and 7 EPO patents. Top assignees: Boehringer Ingelheim International Gmbh, Boehringer Ingelheim Pharmaceuticals, Inc., Aerie Pharmaceuticals, Inc.. Active years: 2005-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: John David Ginn. Retrieved from https://idiyas.com/inventor/john-david-ginn

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 14 (Patent Applications = 6)

% Patents Active = 100.0

CIPO Patents = 2 (Patent Applications = 2)

EPO Patents = 7 (Patent Applications = 8)

Average Co-Inventor Count = 7.5

ph-index = 4

Forward Citations = 68(Granted Patents)

Company Filing History:

8 out of 1,562

Boehringer Ingelheim International Gmbh

patents

3 out of 278

Boehringer Ingelheim Pharmaceuticals, Inc.

patents

2 out of 60

Aerie Pharmaceuticals, Inc.

patents

4. 1 out of 194

Boehringer Ingelheim Pharma Gmbh & Co Kg

patents

5. 1 out of 751

The Rockefeller University

patents

where one patent can have more than one assignee

Years Active: 2005-2026

Loading Chart...

14 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12617785 - Pyrrolo[2,3-b]pyridine-3-carboxamide compositions and methods for ameliorating hearing loss (2026-05-05),

2. 10624882 - Rho kinase inhibitors (2020-04-21),

3. RE46886 - Alkoxy pyrazoles as soluble guanylate cyclase activators (2018-06-04),

4. 9353090 - Heterocyclic carboxylic acids as activators of soluble guanylate cyclase (2016-05-31),

5. 9079880 - Rho kinase inhibitors (2015-07-14),

6. 8952004 - CXCR3 receptor antagonists (2015-02-10),

7. 8906904 - Alkoxy pyrazoles as soluble guanylate cyclase activators (2014-12-09),

8. 8815857 - Soluble guanylate cyclase activators (2014-08-26),

9. 8809326 - Isoquinolinone Rho kinase inhibitors (2014-08-19),

10. 8362249 - CXCR3 receptor antagonists (2013-01-29),

11. 7592353 - [object Object] (2009-09-22),

12. 7550473 - Pyrimidine derivatives useful as inhibitors of PKC-theta (2009-06-23),

13. 7329764 - Substitute benzothiophene compounds (2008-02-12),

14. 6974870 - Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses (2005-12-13),

Title: The Innovative Journey of John David Ginn

Introduction: John David Ginn, a pioneering inventor based in New Milford, CT (US), has made significant contributions to the field of technology with his groundbreaking inventions.

Latest Patents: John David Ginn holds several patents in various technological domains, showcasing his continuous commitment to innovation and creativity.

Career Highlights: Throughout his illustrious career, John David Ginn has been at the forefront of technological advancements, revolutionizing industries with his inventive solutions. His dedication to pushing the boundaries of innovation has earned him recognition as a visionary in the field.

Collaborations: John David Ginn has collaborated with leading tech companies and research institutions to further develop and implement his inventions, fostering a culture of innovation and progress in the industry.

Conclusion: John David Ginn's remarkable journey as an inventor exemplifies the power of creativity, perseverance, and ingenuity in shaping the future of technology. His contributions continue to inspire and drive the world towards a more innovative and advanced future.

Profile summary based on public USPTO records.